Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
35.57
-0.25 (-0.70%)
At close: Mar 20, 2026, 4:00 PM EDT
36.00
+0.43 (1.21%)
After-hours: Mar 20, 2026, 6:49 PM EDT
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Crinetics Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $74.78, which forecasts a 110.23% increase in the stock price over the next year. The lowest target is $52 and the highest is $96.
Price Target: $74.78 (+110.23%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 11 | 11 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $105 → $96 | Buy | Maintains | $105 → $96 | +169.89% | Mar 2, 2026 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $67 | Hold → Strong Buy | Upgrades | $67 | +88.36% | Jan 12, 2026 |
| Citizens | Citizens | Buy Maintains $108 → $105 | Buy | Maintains | $108 → $105 | +195.19% | Jan 8, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $77 → $80 | Buy | Maintains | $77 → $80 | +124.91% | Jan 6, 2026 |
| Citizens | Citizens | Buy Maintains $143 → $108 | Buy | Maintains | $143 → $108 | +203.63% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
63.31M
from 7.70M
Increased by 722.66%
Revenue Next Year
179.67M
from 63.31M
Increased by 183.79%
EPS This Year
-4.98
from -4.95
EPS Next Year
-4.27
from -4.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 82.3M | 224.6M | |||
| Avg | 63.3M | 179.7M | |||
| Low | 36.3M | 130.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 969.6% | 254.8% | |||
| Avg | 722.7% | 183.8% | |||
| Low | 371.2% | 106.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.99 | -3.05 | |||
| Avg | -4.98 | -4.27 | |||
| Low | -5.81 | -5.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.